Imricor Medical secures FDA clearance for 250 hospitals

• Imricor Medical Systems received FDA clearances to expand its NorthStar system and Vision-MR diagnostic catheter to paediatric patients.
• Following the announcement, the company's share price rose 15.24% to close at $2.08.
• The expanded labelling allows the company to target more than 250 children's hospitals in the United States.

Medical device manufacturer Imricor Medical Systems (ASX:IMR) has secured US regulatory clearances to expand its products across 250 paediatric hospitals.

This new development follows the initial regulatory clearances that the company received for adult patients in January.

The clearances allow the company to market both products for children requiring multiple radiation-free cardiac catheterisation procedures.

The company stated that the expanded labels are expected to support its commercialisation strategy by adding an early paediatric channel.

This regulatory milestone provides a clear pathway for the firm to expand its United States market footprint during 2026.

Following the announcement, the Imricor Medical Systems share price was up at $2.08.

The decision aligns with the company's broader strategy to roll out its full magnetic resonance platform into international markets.